Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized, placebo-controlled trial of oral AMT-101 plus adalimumab in moderate to severe ulcerative colitis
2020-002833-13Phase 2Completed
- Sponsor
- Applied Molecular Transport
- Start
- Oct 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing AMT-101 + adalimumab with Placebo + adalimumab (2 arms). Primary endpoint: Mean change in UC-100 score from baseline. Started Oct 2020; status: completed.
02
Drugs
AMT-101
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-002833-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002833-13.